During the corresponding time, Capsovision Inc recorded a revenue increase by 29.6 % year on year, sequentially revenue grew by 56.42 %. While revenue at the Capsovision Inc 's corporate clients
Capsovision Inc's Comment on Sales, Marketing and Customers
The company primarily serves gastroenterologists practicing in clinics and hospitals through an in-house sales team. International sales of CapsoCam Plus are conducted via the in-house sales team and qualified distributors, representing 21% and 23% of total revenue in 2025 and 2024, respectively. The company focuses on the gastrointestinal tract diagnostic market, targeting diseases of the small bowel such as obscure GI bleeding, chronic iron-deficiency anemia, Crohn’s disease, tumors, and polyposis. Capsule endoscopy is utilized as a diagnostic tool due to its simplicity, non-invasiveness, and lower cost compared to enteroscopy. The company is investigating new medical indications, including esophageal conditions and pancreatic cancer, with feasibility and clinical studies planned for 2026 and 2027. It submitted an FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; although not approved, the company plans to resubmit with additional data. The company’s GI-tract capsule endoscopy solution benefits from its sales and marketing structure, technological advancements, and increased telemedicine adoption following FDA clearance for remote ingestion of CapsoCam Plus in December 2024.
Capsovision Inc’s Comment on Sales, Marketing and Customers
The company primarily serves gastroenterologists practicing in clinics and hospitals through an in-house sales team. International sales of CapsoCam Plus are conducted via the in-house sales team and qualified distributors, representing 21% and 23% of total revenue in 2025 and 2024, respectively. The company focuses on the gastrointestinal tract diagnostic market, targeting diseases of the small bowel such as obscure GI bleeding, chronic iron-deficiency anemia, Crohn’s disease, tumors, and polyposis. Capsule endoscopy is utilized as a diagnostic tool due to its simplicity, non-invasiveness, and lower cost compared to enteroscopy. The company is investigating new medical indications, including esophageal conditions and pancreatic cancer, with feasibility and clinical studies planned for 2026 and 2027. It submitted an FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; although not approved, the company plans to resubmit with additional data. The company’s GI-tract capsule endoscopy solution benefits from its sales and marketing structure, technological advancements, and increased telemedicine adoption following FDA clearance for remote ingestion of CapsoCam Plus in December 2024.
Sources:
Capsovision Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Capsovision Inc’s corporate clients.
For your research, we’ve provided 9 tables on Capsovision Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
4.06 %